Back to Main

Faculty Detail    
Name KEVIN A CASSADY
 
Campus Address CHB 118 Zip 0011
Phone 205-996-7910
E-mail kcassady@uab.edu
Other websites
     

Education
Undergraduate  Georgetown University    1986  BA 
Medical School  University of Alabama School of Medicine    1991  MD, Cum Laude 
Residency  University of Washington, Seattle    1994  Residency 
Graduate  University of Chicago     1998  Post Doctoral Fellow 
Fellowship  UAB Division of Infectious Disease    1999  Clinical Fellowship 

Certifications
American Board of Pediatrics  1995 
American Board of Pediatric Infectious Diseases   1999 


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Pediatrics   Ped - Infectious Disease Associate Professor
Secondary  Cell, Developmntl, & Integrative Biology  Cell, Developmntl, & Integrative Biology Associate Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Associate Professor
Center  General Clinical Research Center  Ctr for Clinical & Translational Sci Associate Professor

Graduate Biomedical Sciences Affiliations
Cancer Biology 
Cell, Molecular, & Developmental Biology 

Society Memberships
Organization Name Position Held Org Link
Infectious Disease Society of America   Member   
Pediatric Infectious Disease Society   Member   
Society for Neuro-Oncology   Member   
Society for Pediatric Research   Member   

Research/Clinical Interest
Title
Description
My research focuses on the pathogenic mechanisms by which Herpes simplex virus (HSV) and Human Cytomegalovirus (HCMV) evade innate immune recognition in infected cells. Specifically we are investigating how HSV induces interferon signaling within the initial hours of infection and how interferon induced antiviral genes limit viral replication and neurovirulence. In addition to these intracellular antiviral responses, we are also investigating how HSV down-modulates cell surface receptors during infection in order to avoid innate immune cell detection. Defining the genetic mechanisms enabling viral evasion of the host antiviral defense has allowed us to develop an avirulent HSV/HCMV chimeric virus as an anti-tumor therapeutic. Preclinical studies show that the chimeric HSV is superior to existing HSV oncolytic viruses. The chimeric HSV is under patent protection and through an NCI RAID award clinical grade virus is currently being manufactured. Through recent SPORE funding we are advancing the chimeric HSV to Phase I clinical trial for patients with Glioblastoma multiforme.